Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AB, abating, abbreviated, accretion, addressed, adjuvant, African, Amolyt, amyotrophic, Anavex, antagonist, antibody, antigen, antisense, approx, aquaporin, Aquaporumab, arginine, Asian, asymptomatic, attack, azathioprine, Aziyo, background, Bacon, bacteria, bacterial, bacterium, Balkan, Baxalta, Baxter, Belgium, Biden, Bio, bioavailability, Biohaven, Biopharm, blarcamesine, block, blocking, booster, Boston, bought, Box, Brainstorm, Brigham, broadly, Bulgaria, Bulletin, bundle, burn, calcium, captured, Celanese, cell, cerebrospinal, cetrorelix, CH, chewing, chlamydia, choose, chronic, Cleara, cleavage, Clene, clonidine, CNS, commercialisation, commercialise, Consilient, contractility, convey, cord, Covidien, CP, Creative, criterion, crucial, cultural, cum, cycle, deep, degenerative, Democratic, Denmark, depleting, depth, die, digit, dismutase, distinct, docket, Dopaminergic, DPRK, drastically, DUPK, ECL, ectopic, edaravone, eighty, electric, encoding, energy, enspryng, Entera, EOOD, er, excellent, exhaust, expedient, fast, fertilization, fetal, fever, fictional, fluid, footage, France, Fratta, Fulbright, fusion, GB, Gehrig, GHRYVELIN, Giuliano, glutamate, GMP, grace, great, greatly, gut, hallmark, Hardy, harmonized, Helixmith, hepatocyte, histocompatibility, horizon, hypoparathyroidism, HypoPT, immunogenic, immunology, immunomodulation, immunomodulatory, immunosuppressive, inclusion, inexpensive, infected, infecting, infection, infertility, interdependent, interrelated, intestinal, Intracoastal, invasion, irreversible, Italy, Joerg, KGaA, kilogram, Kim, kinase, Kingdom, labor, landlord, Latin, laude, Laval, lengthy, leveraging, lifelong, lifetime, Lind, living, Lou, LSA, Lu, lump, Lundbeck, Lybrand, macmorelin, Macro, macrocyclic, MAH, mainstay, Mallinckrodt, Martinsried, Masitinib, maternal, matrix, mediation, meditech, MegaPharm, men, mesenchymal, MHC, mice, milligram, Ministry, miscarriage, misdirected, misfolding, Missouri, Mitsubishi, modification, mofetil, momentum, monoclonal, motor, motoric, mouse, mucosal, multinational, muscle, mycophenolate, myeloperoxidase, Nanomedicine, nerve, neurodegeneration, neurological, neuronal, neurotransmitter, newly, ninety, NK, NMOSD, ocular, official, Omicron, opportunistically, optic, optica, overallotment, oxygen, Paediatric, parathyroid, Parkinson, PD, Peter, PharmBio, plasmid, platform, polypeptide, Port, Prasinemuzab, predominant, pregnancy, processed, progression, progressive, propagation, proper, prophylactic, prorated, protein, Prothena, PTH, pubertal, PwC, Queensland, rapid, reactive, ready, recombinant, recoup, refiled, regeneration, relapsing, reldesemtiv, renegotiate, renegotiation, reproductive, respiratory, revert, Riluzole, risky, rituximab, Roche, ROK, Rose, route, Rudel, RUK, Russian, SA, salmonella, sentence, serum, session, sexually, Sheffield, Shire, Shook, skeletal, sooner, Spain, spinal, square, standalone, stay, stem, sublicense, sublicensing, suitable, superoxide, supervisory, supplementary, suppressing, Supreme, susceptible, Switzerland, Syn, synuclein, Takedo, talking, Tanabe, TG, tissue, trachoma, tract, tradename, TransCon, transgenic, transmitted, transposing, Treasurer, troponin, Turkey, Turpin, twenty, Typhi, typhoid, tyrosine, ublituximab, UCB, unallocated, unamortized, unaudited, undergo, undergoing, underwent, underwritten, undesirable, undisclosed, unsatisfied, uplizna, upper, USA, Utrecht, variant, vascular, verdiperstat, viral, visual, vital, vitamin, vitro, walking, war, weekly, Wischhusen, WO, wrong, Wuerzburg, Zilucoplan
Removed:
Abbott, affinity, agreeing, apifiny, Ardana, Armune, assembled, assist, attestation, attribution, baby, banking, baseline, Brian, build, cancelled, Cardiff, chemotherapy, China, CICA, collected, commencing, commit, comparator, conditional, conjugate, content, contingency, CRL, crossover, curtail, cytotoxic, Dean, decided, Deputy, devoting, dismissal, disorazol, distribute, distributing, documenting, Donald, doubtful, doxorubicin, du, Educational, effected, electrocardiogram, elevating, Elliott, EMD, enabling, endocrine, endometrial, endpoint, epidemiological, estimation, EstroGel, EuroPharma, exporting, Faculty, FCA, FCPA, Fellow, finalize, float, Floor, Garrison, generation, globe, Governor, graduating, HEC, Hong, IFRIC, importing, India, inVentiv, investigator, John, Johnson, Kong, lack, LHRH, Macau, managerial, Medal, median, MMA, modeling, monetize, Montreal, multijurisdictional, myocardial, nomination, obligated, Ordre, Orient, origin, parallel, PDUFA, pharmacoeconomic, pharmacovigilance, plasma, practicing, prognostic, prolongation, promoting, PROREIT, prostate, Pte, QT, Rafa, rDNA, receivership, recoverability, Rector, regaining, remote, renamed, renewed, replicate, repolarization, repurchase, requested, revise, RMS, rolled, Saizen, secretagogue, selection, selective, Serono, shifted, showed, somatropin, southeast, SPA, Specialised, spend, spent, sponsorship, statistically, Stikeman, sublicensee, suburb, succeed, successive, suggested, survival, suspend, tabular, Taiwan, Tech, transition, transporting, Trump, trustee, TTA, Tulane, turnover, uncollectible, Universit, uptake, verifiable, vision, Ward, West, wrote, York, zoptarelin, zoptec, Zoptrex, ZoptrexTM
Filing tables
Filing exhibits
CSCI similar filings
Filing view
External links
Exhibit 13.2
Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Aeterna Zentaris Inc. (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Giuliano La Fratta, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: March 28, 2022
/s/ Giuliano La Fratta | |
Giuliano La Fratta | |
Chief Financial Officer |